153 related articles for article (PubMed ID: 20038320)
1. [Clinical features of hypersensitivity reactions to oxaliplatin among Chinese colorectal cancer patients].
Zhao Y; An X; Xiang XJ; Feng F; Wang FH; Wang ZQ; Xu RH; He YJ; Li YH
Chin J Cancer; 2010 Jan; 29(1):102-5. PubMed ID: 20038320
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan.
Shibata Y; Ariyama H; Baba E; Takii Y; Esaki T; Mitsugi K; Tsuchiya T; Kusaba H; Akashi K; Nakano S
Int J Clin Oncol; 2009 Oct; 14(5):397-401. PubMed ID: 19856046
[TBL] [Abstract][Full Text] [Related]
3. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
[TBL] [Abstract][Full Text] [Related]
4. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
Van Cutsem E; Verslype C; Beale P; Clarke S; Bugat R; Rakhit A; Fettner SH; Brennscheidt U; Feyereislova A; Delord JP
Ann Oncol; 2008 Feb; 19(2):332-9. PubMed ID: 17986625
[TBL] [Abstract][Full Text] [Related]
5. A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer.
Qvortrup C; Jensen BV; Fokstuen T; Nielsen SE; Keldsen N; Glimelius B; Bjerregaard B; Mejer J; Larsen FO; Pfeiffer P
Ann Oncol; 2010 Jan; 21(1):87-91. PubMed ID: 19622596
[TBL] [Abstract][Full Text] [Related]
6. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.
Argyriou AA; Velasco R; Briani C; Cavaletti G; Bruna J; Alberti P; Cacciavillani M; Lonardi S; Santos C; Cortinovis D; Cazzaniga M; Kalofonos HP
Ann Oncol; 2012 Dec; 23(12):3116-3122. PubMed ID: 22865779
[TBL] [Abstract][Full Text] [Related]
7. Hypersensitivity reactions to oxaliplatin in two asian patients.
Ng CV
Ann Pharmacother; 2005 Jun; 39(6):1114-8. PubMed ID: 15886290
[TBL] [Abstract][Full Text] [Related]
8. High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.
Kidera Y; Satoh T; Ueda S; Okamoto W; Okamoto I; Fumita S; Yonesaka K; Hayashi H; Makimura C; Okamoto K; Kiyota H; Tsurutani J; Miyazaki M; Yoshinaga M; Fujiwara K; Yamazoe Y; Moriyama K; Tsubaki M; Chiba Y; Nishida S; Nakagawa K
Int J Clin Oncol; 2011 Jun; 16(3):244-9. PubMed ID: 21243395
[TBL] [Abstract][Full Text] [Related]
9. Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
Ohta H; Hayashi T; Murai S; Shiouchi H; Ando Y; Kumazawa S; Ito K; Ikeda Y; Matsuoka H; Maeda K; Kawada K; Yasuda K; Yamada S
Cancer Chemother Pharmacol; 2017 May; 79(5):1021-1029. PubMed ID: 28391355
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
Doi T; Boku N; Kato K; Komatsu Y; Yamaguchi K; Muro K; Hamamoto Y; Sato A; Koizumi W; Mizunuma N; Takiuchi H
Jpn J Clin Oncol; 2010 Oct; 40(10):913-20. PubMed ID: 20462981
[TBL] [Abstract][Full Text] [Related]
11. Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study).
Matsuda C; Honda M; Tanaka C; Fukunaga M; Ishibashi K; Munemoto Y; Hata T; Bando H; Oshiro M; Kobayashi M; Tokunaga Y; Fujii A; Nagata N; Oba K; Mishima H
Int J Clin Oncol; 2016 Jun; 21(3):566-72. PubMed ID: 26475356
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
Seymour MT; Thompson LC; Wasan HS; Middleton G; Brewster AE; Shepherd SF; O'Mahony MS; Maughan TS; Parmar M; Langley RE; ;
Lancet; 2011 May; 377(9779):1749-59. PubMed ID: 21570111
[TBL] [Abstract][Full Text] [Related]
13. Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
Kim SH; Shin SJ; Kim SY; Lee SH; Park YS; Park SH; Lee KH; Kim TW; Hong YS; Ahn JB
Cancer Chemother Pharmacol; 2012 Jan; 69(1):91-7. PubMed ID: 21607556
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
Karacetin D; Yalcin B; Okten B; Ozturk S; Maral O; Incekara O
J BUON; 2009; 14(4):605-8. PubMed ID: 20148449
[TBL] [Abstract][Full Text] [Related]
15. [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
Zhao WY; Chen DY; Qi Q
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):295-8. PubMed ID: 21575503
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Rothenberg ML; Cox JV; Butts C; Navarro M; Bang YJ; Goel R; Gollins S; Siu LL; Laguerre S; Cunningham D
Ann Oncol; 2008 Oct; 19(10):1720-6. PubMed ID: 18550577
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer.
Li YH; Luo HY; Wang FH; Wang ZQ; Qiu MZ; Shi YX; Xiang XJ; Chen XQ; He YJ; Xu RH
J Cancer Res Clin Oncol; 2010 Apr; 136(4):503-10. PubMed ID: 19777259
[TBL] [Abstract][Full Text] [Related]
18. Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer.
Moreno-Solórzano I; Ibeas-Rollan R; Monzó-Planella M; Moreno-Solórzano J; Martínez-Ródenas F; Pou-Sanchis E; Hernández-Borlan R; Navarro-Vigo M; Ortigosa-Rodríguez S; Gel-Moreno B
Clin Colorectal Cancer; 2007 Sep; 6(9):634-40. PubMed ID: 17945035
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
[TBL] [Abstract][Full Text] [Related]
20. Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer.
Pfeiffer P; Hahn P; Jensen HA
Acta Oncol; 2003; 42(8):832-6. PubMed ID: 14968944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]